Chatham Capital Group’s Gilead Sciences GILD Stock Holding History

Chatham Capital Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,403	Closed	-$276K	–	147
2017 Q3	$276K	Sell	3,403 -550	-14%	-$42.1K	0.08%	129
2017 Q2	$280K	Sell	3,953 -700	-15%	-$46.6K	0.08%	133
2017 Q1	$316K	Hold	4,653	–	–	0.09%	127
2016 Q4	$333K	Sell	4,653 -700	-13%	-$52K	0.1%	119
2016 Q3	$424K	Sell	5,353 -1,025	-16%	-$83.3K	0.13%	109
2016 Q2	$532K	Hold	6,378	–	–	0.16%	96
2016 Q1	$586K	Hold	6,378	–	–	0.18%	91
2015 Q4	$645K	Sell	6,378 -50	-0.8%	-$5.2K	0.21%	84
2015 Q3	$631K	Sell	6,428 -54	-0.8%	-$6K	0.21%	86
2015 Q2	$759K	Sell	6,482 -968	-13%	-$106K	0.21%	91
2015 Q1	$731K	Hold	7,450	–	–	0.21%	91
2014 Q4	$702K	Sell	7,450 -700	-9%	-$72.4K	0.21%	95
2014 Q3	$868K	Buy	+8,150	New	+$798K	0.27%	75

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chatham Capital Group's GILD Position: Q4 2017 in Review

Chatham Capital Group sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 3,403 shares — an estimated $276K sold.

Chatham Capital Group first reported a position in GILD in Q3 2014 and held it in 13 quarters. The position peaked at $868K in Q3 2014. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

Chatham Capital Group reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
Chatham Capital Group sold 3,403 Gilead Sciences shares in Q4 2017, an estimated $276K.
Chatham Capital Group first reported a position in Gilead Sciences in Q3 2014 and held it in 13 quarters.
Chatham Capital Group's Gilead Sciences position peaked at $868K in Q3 2014.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Chatham Capital Group's 13F filing for Q4 2017, filed 1 Feb 2018.